Event Announcements

The Science of Pain and its Management 2016- Press Release


The Science of Pain and its Management 2016


 This event will discuss emerging research relating to the physiology, psychology and pharmacology of pain, and its assessment and management.

Chronic pain is a devastating health problem, and currently available treatments, including opioids and NSAIDS, often lack adequate efficacy leaving pain unrelieved.  Tracey Ignatowski, PhD,  (Assistant Professor of the Department of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, The State University of New York at Buffalo), is the lead investigator of several studies demonstrating that heightened levels of the immune signalling protein, TNF-α, in the brain are a viable target for analgesia. Dr. Ignatowksi remarks, “Our understanding of the regulation of brain function and neuropathic pain by the immune system may be of fundamental importance to advancing our ability to provide new ways to help patients with intractable neurological disorders.”

While Professor Marino Convertino (University of North Carolina, USA) will discuss a unique signalling mechanism for opioid-dependent pain hypersensitivity. “The elucidation of this unique signalling mechanism provides a platform for the development of novel pharmacological strategies and/or therapeutic protocols involving the use of opiates and beta blockers.”

Dr Pippa Hawley (BC Cancer Agency, Vancouver, Canada) will talk about how the prognosis of patients receiving a cancer diagnosis has changed quite dramatically over the last few years, and that we have to think more about cancer as a chronic disease than ever before. “Non-opioid methods of cancer pain management need to be given a much higher priority in those with long life expectancies, and we as prescribers need to be much more alert to the emergence of addiction as a clinically relevant problem in 21st century cancer patients.”

Professor Graeme Jones (University of Tasmania, Hobart TAS, Australia) will review the evidence regarding pain in osteoarthritis and the implications for therapy. “Pain due to arthritis is extremely common in people aged over 50. Recent studies have shown that this pain has multiple causes. This, in turn, is leading to better treatment outcomes as therapies can be fine tuned so they best target the cause of the pain.”

While Dr. Luana Colloca, (University of Maryland School of Medicine, Baltimore, USA) will discuss placebo analgesia as a model to produce pain relief in individuals by virtue of expectations and anticipations of a benefit. Learned placebo analgesic effects can be elicited in patients suffering from pain disorders even when pain appears to be refractory to conventional pharmacological interventions .

Other talks include – Physical pain threshold and tolerance in self-harm (Dr. Olivia J. Kirtley, University of Glasgow, Glasgow, United Kingdom), Protective responses in pain: a closer look at perceptions of stiffness in chronic back pain (Dr. Tasha Stanton, University of South Australia) and Phantom limb pain in lower limb amputees (Dr Cliff Richardson, University of Manchester, UK).


Who Should Attend:This event is aimed at research scientists, physicians and pharmaceutical professionals working on both basic pain research and clinical aspects of pain, including pain management.

The event will be recorded and available for all registered delegates up to a month after the event.  So if you can’t manage all the days, or the different time zones, you can still have access to the full event.

Invited speakers and their talks include:

Talk titleSpeakerAffiliationCountry
Central GABA-C receptors and anti-nociceptionProfessor Sastry BhagavatulaThe University of British ColumbiaCanada
The use of animal models to elucidate the pathophysiology of "dysfunctional pain", an unexplained and formidable pain categoryDr. Yukinori NagakuraAomori UniversityJapan
Where does the pain come from in osteoarthritis?Professor Graeme Jones University of TasmaniaAustralia
Morphine - P2Y12 inhibitors, a drug-drug interaction in STEMI patientsProfessor Jacek KubicaNicolaus Copernicus UniversityPoland
The roles of Clathrin Heavy Chain-22 in human pain and touch developmentDr. Mike NahorskiUniversity of CambridgeUnited Kingdom
Gonadal Hormones and PainProfessor Anna Maria AloisiUniversità degli Studi di SienaItaly
Novel morphine analogue 14-O-methylmorphine with high mu opioid receptor agonist efficacy, selectivity and affinityDr Ferenc ZádorHungarian Academy of SciencesHungary
Targeting mRNA translation regulation to alleviate nociceptor plasticity driving chronic painDr. Theodore PriceUniversity of Texas at DallasUnited States
Stancak, A. Brain electrophysiological representation of multidimensional subjective experience of pain during noxious laser heat stimulationDr. Andrej StancakUniversity of LiverpoolUnited Kingdom
Role of 6TM-mOR and GPCR heterodimerization in opioid induced hyperalgesia Dr. Marino ConvertinoUniversity of North CarolinaUnited States
What are the effects of therapeutic play intervention on children’s perioperative anxiety, negative emotional behaviour, and postoperative pain?Dr. HE Hong-GuNational University of SingaporeSingapore
TBCDr. Felipe FregniHarvard Medical SchoolUnited States
Conceptual framework of pain in persons with mild traumatic brain injury/concussion
Dr. Tatyana MollayevaUniversity of TorontoCanada
Clinical assesment of central sensitization in patients with musculoskeletal painDr. Ramakrishnan ManiUniversity of OtagoNew Zealand
Design of Novel Multivalent Ligands for the Treatment of Prolonged and Neuropathic Pain Without the Development of Addiction and Other ToxicitiesProfessor. Victor J. HrubyUniversity of ArizonaUnited States
Adapting the cancer pain management paradigm to non-cancer pain and survivorshipDr. Pippa HawleyBC Cancer AgencyCanada
Physical pain threshold and tolerance in self-harm: methodological challenges and future directionsDr. Olivia J. KirtleyUniversity of GlasgowUnited Kingdom
Chronic Pain Among Opioid Addiction Patients: Identifying and Managing an Important Risk FactorDr. Zainab SamaanMcMaster UniversityCanada
Decreasing Tumor Necrosis Factor-alpha Solely in the Brain for Treatment of Neuropathic PainProfessor Tracey A. Ignatowski University at BuffaloUnited States
Challenges and success stories for Pain management in developing countriesDr. Mary Ann MuckadenTata Memorial CentreIndia
Protective responses in pain: a closer look at perceptions of stiffness in chronic back painDr. Tasha StantonThe University of South AustraliaAustralia
Behavioural pain assessment tool development and the development and initial testing of a meta toolDr. Julie GregoryUniversity of ManchesterUnited Kingdom
TBCDr. Luana CollocaUniversity of Maryland School of Nursing University of Maryland School of MedicineUnited States
Inpatient headache managament for migraines and chronic daily headachesDr. Priyanka ChaudhryBaylor Comprehensive Headache CenterUnited States
Chronic Pain and Addiction: the CrossroadsDr. Peter PrzekopLoma Linda UniversityUnited States
Where is pain in the brainProfessor Emeritus Amos D KorczynTel Aviv UniversityIsrael
Phantom limb pain in lower limb amputees: a discussion of the potential mechanismsDr. Cliff RichardsonUniversity of ManchesterUnited Kingdom
The impact of baroreflex sensitivity for the treatment of chronic painDr. Kati ThiemePhilipps-University of MarburgGermany
Disconnecting pain - neurosurgical treatments for intractable oncological painDr. Ido StraussTel Aviv UniversityIsrael
Gentian Violet: A Potential Treatment For Cutaneous LeishmaniasisDr Marc KaramUniversity of BalamandLebanon

Registration Fees

Register Now For This Euroscicon Event

A Euroscicon live streamed event gives you access to a wider range of international speakers at a fraction of the cost of a real world event.  Furthermore, you no longer have to worry about travel or accommodation expenses,  or any arrangements you have which clash with our events.

Agend   Speakers   Abstract book

Latest Euroscicon Tweets

Error: You currently have access to a subset of Twitter API v2 endpoints and limited v1.1 endpoints (e.g. media post, oauth) only. If you need access to this endpoint, you may need a different access level. You can learn more here: https://developer.twitter.com/en/portal/product